

BIOSPHERE

UTAH'S LIFE SCIENCES INDUSTRY MAGAZINE

2026



UTAH'S INCUBATORS

BUILDING TOMORROW

CONTRACT
MANUFACTURERS 13

MEDTRONIC
ACQUIRES SCIENTIA 7

NELSON LABS
LOCAL TO GLOBAL 41



GROWING BUSINESS GROWING OPPORTUNITY™



PRICE

COMMERCIAL REAL ESTATE
DEVELOPMENT AND INVESTMENT

LETTER FROM THE CHAIR



Welcome to the 2026 *Biosphere Magazine*, BioUtah's annual spotlight on Utah's booming life sciences sector, an industry driving innovation with a vibrant mix of rapid-growth startups, advanced diagnostics, specialized drug development,

and foundational medtech giants.

Utah has quickly evolved into an epicenter for healthcare breakthroughs. The foundation of this success is captured in the motto, "It all starts here" —right here in the Beehive State.

The articles that follow celebrate this theme. They reflect an ecosystem whose milestones are deeply rooted in a unique Utah blend of vision, entrepreneurship, and collaboration. There's no question that Utah's life sciences community is making big things happen from the bottom up.

From lab bench to market launch, our cover story looks at how Utah's expansive incubator network fuels the next

wave of life sciences ventures. We also take a closer look at industry leaders: Azunic's animal-free drug testing platforms, Medtronic's acquisition of home-grown Scientia Vascular, advanced diagnostics at ARUP Laboratories, and Merit Medical's CEO succession. Finally, we map out the state's broader bio-infrastructure stretching from Logan to St. George, and share what's new on the ground as new companies take up residence.

Whether you are a researcher, executive, an investor, supply chain provider, engineer, quality expert, financial/marketing/sales professional, or manufacturing support, or simply a curious reader, we invite you to explore the pages of *Biosphere* and connect with our industry's collective mission to build the solutions right here in Utah that will improve and save patients' lives worldwide.

Sincerely,

Chair, Board of Directors, BioUtah

Vice President, Government Affairs, Merit Medical



A Publication by BioUtah
230 East South Temple, Suite 100
Salt Lake City, UT 84111
801.867.4061
BioUtah.org

Distributed by *Utah Business*.

CONTRIBUTORS

Mike Anderson
Erin Barry
David Bearss
Collin Begley
Denise Bell
Matt & Cara Bills
Justin Brunson
Lindsay Cleverly
Sarah Comstock
Kate Corr
Spencer Cox
Dan Craven
Kelvyn Cullimore
William Cupelo
Aaron Davis
Jack Flavin
John Flavin
Ann Gargiulo

Courtney Geary
Tracy George
Shawn Gibbs
Nate Gibby
Mike Gillem
Adam Hattan
Joe Heeb
Jerry Henley
Kelly Himle
Dan Housley
Nick Hulme
Taylor Janney
Charles Jensen
Chris Kirk
Jim Kwan
Chris London
Ashlee McBride
Kevin Miller

Lauryn Narramore
Tim Nieman
Aspen Orton
Nick Pennebaker
Elizabeth Romero
Katie Romney
Kapil Sharma
Logan Sheffield
Bonne Stray
David Taylor
Natalie Themm
Gracie Tidwell
Clark Turner
Scott Vane
Jeff Walker
Devin Williamson
Chris Wilson

CONTENTS

UTAH'S INCUBATORS


CENTER FOR
MEDICAL INNOVATION
UNIVERSITY OF UTAH


nnovations
THE WAY


UVB
CAPITAL


Portal
Innovations

BUILDING
TOMORROW

22

ON THE COVER

UTAH'S CONTRACT MANUFACTURERS

Partners in Medical
Innovation

13

WHAT'S NEW

Utah's Life Sciences
Latest Scoop

30

UTAH'S LIFE SCIENCES LATEST SCOOP



pharmaceutical
precision
solid tumors.

Trillium's platforms
es, Patient Access, and
ed to change
tic impact
radiotherapeutic for
ft tissue sarcomas.

Commercial success
location in meeting

The Salt Lake City
and transportation
force, and pro
and radiopharmacy
to the complex req
development and
state and local offi
and partner, the W
company's decision

Ratio's expansion
cancer therapies re
the reliable manu

MEDTRONIC ACQUIRES SCIENTIA

Advancing the Future
of Stroke Care

7

6

GOVERNOR'S LETTER

Life Sciences is a Force
in Utah's Economy

35

FROM MYSTERY ILLNESS TO DIAGNOSIS

ARUP Explains Why Lab-
Developed Tests Matter

10

WORKFORCE CONNECT

Linking Industry to Utah's
Life Sciences Talent

38

LIFE SCIENCES AWARDS 2025

Recognizing Exceptional
Leadership and Service

18

LANDMARK APPROVAL

Denali's FDA-Approved
Hunter Syndrome Treatment

41

LOCAL TO GLOBAL

Nelson Labs: Another
Utah Success Story

20

TRANSFORMING DRUG DEVELOPMENT

Azunic's Animal-Free Testing

44

LEADING WITH PURPOSE

Meet Martha Aronson,
Merit's New CEO

28

WHERE LIFE SCIENCES IS HAPPENING

Utah's Life Sciences
Geographic Distribution

47

A PURE PLAY STORY

How Kolosis is Building
a Biologics Powerhouse

It started with a messy whiteboard.

That gave patients a clean slate.



BIOUTAH

Visit [FightofOurLives.com](https://fightofourlives.com)
to learn more.



LETTER FROM UTAH'S GOVERNOR



Dear Reader,

Utah has topped the list in *U.S. News & World Report's* Best States rankings for the fourth consecutive year. The state's \$21.6 billion life sciences industry—whose combined direct and indirect economic footprint sparks commercial growth and improves health—helps to propel this winning streak.

Our life sciences ecosystem is one of the fastest-growing in the U.S. We take pride in the fact that Utah's unique culture of collaboration gives rise to impactful partnerships between our vibrant academic research centers, incubators, investors, and companies large and small.

My Governor's Office of Economic Development continues to champion the industries that keep Utah at the forefront of innovation and economic prosperity. Our flourishing life sciences field stands out among these. We work hand-in-hand with BioUtah, the industry's premier trade association, to advance breakthroughs in medical devices, diagnostics, and drug therapies. Furthermore, state and local initiatives are strengthening our workforce, supporting new startups, and boosting manufacturing capacity.



Utah is the apex of the Intermountain West for invention, career, and community. We invite you to discover why the Beehive State is a global bioscience hub and why the future of healthcare is **right here!**

Sincerely,

A handwritten signature in black ink, which appears to read "Spencer J. Cox".

Spencer J. Cox
Governor of Utah

Medtronic ACQUIRES




What began in a garage in Reno, NV, led by founder John Lippert, has now grown into one of Utah's most notable medical technology success stories.

In March 2026, global healthcare technology leader Medtronic announced a definitive agreement to acquire Scientia Vascular for \$550 million, combining Scientia's breakthrough neurovascular access technologies with Medtronic's global stroke treatment platform. The acquisition marks a major milestone not only for Scientia, but also for Utah's expanding medical device and life sciences ecosystem.

Founded in 2007 by entrepreneur and engineer Lippert, Scientia was built around a simple idea: better access leads to better outcomes. In 2013, Scientia relocated to Salt Lake City, attracted by Utah's engineering talent, collaborative business climate, and growing medtech community.



Scientia Vascular Founder John Lippert.




ADVANCING THE FUTURE OF STROKE CARE

Over the next decade, Scientia emerged as a recognized innovator in neurovascular access, developing specialized guidewires and catheter technologies that help physicians navigate the brain's delicate vasculature.

Those innovations play a critical role in stroke intervention, where speed and precision can mean the difference between recovery and permanent disability. During ischemic stroke procedures, physicians must rapidly navigate complex blood vessels to reach and remove a clot before irreversible brain damage occurs. Scientia's microfabricated guidewires and catheters—including the Aristotle™, Plato™, and Socrates™ product families—were engineered to improve navigation, stability, and procedural efficiency during some of the most demanding neurovascular procedures performed today.

"The brain is a complex environment," said Linnea Burman, senior vice president and president of Medtronic Neurovascular, in announcing the acquisition. "Scientia has developed best-in-class products that more safely and effectively enable access, with disruptive technology across the neurovascular portfolio."



Scientia CEO Rick Randall said the acquisition represents an opportunity to bring the company's innovations to a much larger patient population.

"Our mission has always been to provide physicians with better tools to reach and treat patients safely and efficiently," said Randall. "By joining Medtronic, we can accelerate that mission globally and help more stroke patients benefit from the technologies our team has worked so hard to develop."

"This combination of best-in-class products and treatment therapies, combined with best-in-class access, will be incredibly powerful in simplifying procedures for physicians, saving critical time, and improving patient outcomes," added Burman.

The acquisition also highlights Utah's growing reputation as a hub for medical device innovation and advanced manufacturing. From its headquarters in West Valley City, Scientia evolved from a startup into a company employing hundreds of people and contributing to the state's leadership in neurovascular technology.

For Utah's life sciences community, the transaction reflects the strength of an ecosystem that continues to attract entrepreneurs, investment, and global attention. For patients around the world, it means broader access to technologies designed to improve outcomes during some of medicine's most time-sensitive and life-threatening emergencies. 





Moving healthcare forward, together

Anticipating your needs before they arise is how we help you stay ahead. For more than 125 years, BD has known one thing to be true—for healthcare professionals to be at their best, they need the best. That's why we're continually envisioning the solutions of tomorrow by innovating today.

Visit [bd.com](https://www.bd.com) to learn more.



BD


Advancing the
world of health™



WORKFORCE CONNECT:



UTAH SYSTEM OF
HIGHER EDUCATION
TALENT READY UTAH



TALENT HUB

As the hub of all things life sciences in the state of Utah, BioUtah stands as an important liaison between industry and academia. A common complaint has been the inability of either party to form long-lasting partnerships to support internship recruitment. Academic institutions have scores of students seeking internships but have limited resources to develop rapport with the broad array of life sciences companies in the state. Likewise, life sciences companies struggle to establish sustained relationships with the numerous academic institutions. Most companies would ideally like to recruit interns from an assortment of academic institutions, but that requires significant effort to make the right connections.

Working with the Talent Ready Utah team from the Utah System of Higher Education over the past few years, BioUtah has helped develop an internship exchange named the Talent Hub that facilitates connecting intern candidates from all colleges and universities in Utah, public and private, with companies seeking to hire interns. It is simple for companies to post internship opportunities on the Talent Hub exchange and review posted resumes from interns.

For over a decade, Utah has been one of the fastest-growing life sciences hubs in the nation. This growth is fueled in part by a strong and educated workforce. To sustain continued growth in the industry, workforce enhancements are also required. BioUtah continues to work with the state legislature to provide funding for educational degrees and training programs that support industry growth. In addition, BioUtah is pleased to announce two new tools designed to further strengthen Utah's life sciences workforce: The Talent Hub and the BioUtah Job Center.



LINKING INDUSTRY TO UTAH'S LIFE SCIENCES TALENT



BIOUTAH



It is just as easy for students to post their resumes and examine the opportunities on the exchange.

For more information about the Talent Hub, contact BioUtah. The more companies engage with this tool, the more robust and trusted it becomes for companies, academic institutions, and interns.

BIOUTAH JOB CENTER

BioUtah is asked frequently what jobs are available in the life sciences industry in Utah. Until now, there has been no central repository where jobs can be posted or links provided to job boards. In response, BioUtah has created the BioUtah Job Center.

The Job Center will be a feature on BioUtah's website. BioUtah members will be able to post jobs on the Job Center site via BioUtah's Info Hub. Jobs can be posted individually, or companies can post a link to their own job site. The goal of the BioUtah Job Center is to provide a single place where those interested in jobs in the life sciences can go to explore job opportunities.

Member companies are encouraged to start posting jobs to the site and to work with BioUtah to link to job postings on company websites or job boards.

Providing workforce resources and connectivity is an important way BioUtah provides value to its members and strengthens the workforce supporting the growth of the life sciences industry.

We invite all members to take full advantage of the BioUtah Job Center to enhance recruitment efforts and expand socialization of job opportunities with your company. 



ASCENT SURGICAL LAB

Enter an immersive surgical environment with advanced operating room technology for collaborative device testing and hands-on procedural training, complemented by dedicated learning and breakout spaces.



CENTER FOR
MEDICAL INNOVATION
UNIVERSITY OF UTAH



cmi.uofuhealth.org



Launch and grow in a premier medtech incubator with private offices, advanced prototyping and testing resources, and direct access to a community of health care experts and industry innovators.

STARTUP INCUBATORS

UTAH'S CONTRACT MANUFACTURERS

PARTNERS IN MEDICAL INNOVATION



Founded in 1994, Biomerics is a leading vertically integrated medical device contract manufacturer serving the interventional device market. Biomerics has nine locations in the U.S., two in Costa Rica, and one in the Dominican Republic. With over 900,000 square feet of facilities globally, Biomerics provides engineering design and development services, technology transfer manufacturing services, and contract manufacturing services, including sterilization and packaging, for medical device components, sub-assemblies and finished medical devices. Comprehensive metals and plastics manufacturing capabilities combine with unique engineering depth to make Biomerics a trusted partner to leading original equipment manufacturers (OEMs).



Biomerics' capabilities support the full range of components & assemblies for innovative devices.

"A critical differentiator for Biomerics that we continue to invest in is that we are not a manufacturing company with a couple of engineers," said Biomerics CEO Arun Mohan. "We are an innovation- and engineering-driven company

that is able to do manufacturing at scale. And there's a difference. That's why our partners come to us to solve complex problems and trust us with their most complex, innovative devices."

Biomerics collaborates with customers at every stage of development, helping bring medical device innovations to life with a scalable, sustainable, high-quality approach. From helping OEMs design their devices for scalability to accelerating the design cycle for second-generation devices, Biomerics' new product development and broader engineering teams push the envelope of interventional device innovation, making these innovations available to more patients in Utah and worldwide.



ZIEN Medical

ZIEN Medical Technologies is redefining what it means to be a contract manufacturing partner in Utah's life sciences industry. Founded in 2009 and headquartered in Utah, ZIEN operates as a fully integrated Contract Design and Manufacturing Organization and Manufacturer of Record, assuming complete legal, regulatory, and compliance accountability on behalf of its clients. This model allows medical device companies to remain focused on clinical strategy and commercialization while ZIEN manages everything in between.

ZIEN's comprehensive services portfolio spans the full product lifecycle: mechanical, electrical, software, and firmware engineering; cleanroom assembly; sterile packaging; validated ethylene oxide sterilization; and global distribution. Its 24,000+ square feet of ISO-certified cleanroom facilities are equipped to support Class I and Class II disposable and durable device programs. ZIEN delivers FDA 510(k), CE Mark, ISO 13485, MDSAP, and EU MDR submissions, supported by a licensable Quality Management System that saves clients 12 to 18 months of infrastructure setup time.



Zien Medical's cleanroom manufacturing.

The outcomes are measurable. ZIEN clients achieve an 82% commercialization success rate, compared to the 25% industry average. Since inception, the team has completed 46+ FDA product registrations and delivered an average of \$250,000 in program savings per engagement through shared validations and consolidated vendor management. One CEO of a U.S. medical device manufacturer put it this way: "ZIEN didn't behave like a contract manufacturer. They acted like a commercialization partner." It doesn't get better than that.



ATL Medical is a contract development and manufacturing organization delivering end-to-end solutions that transform customer concepts into life-changing medical technologies. From early-stage design support through scalable manufacturing, ATL partners closely with leading medtech original equipment manufacturers to translate complex product specifications into high-performance, manufacturable systems. Capabilities span advanced energy medical devices, interconnect solutions,

electromechanical assemblies, catheter and minimally invasive device manufacturing, and system-level integration. By combining engineering expertise with vertically integrated manufacturing, ATL reduces design-to-production timelines while ensuring quality, reliability, and regulatory compliance across every phase of development.



ATL's precision-molded components support performance, quality, & scalability requirements of complex medical devices.

Contract manufacturers play a critical role in accelerating medical innovation by bridging design intent with manufacturability. ATL's collaborative model enables customers to de-risk development, optimize cost structures, and bring differentiated technologies to market faster, particularly in high-growth segments such as cardiovascular, electrophysiology, electrosurgical, and camera-based imaging.

With a global manufacturing footprint including Costa Rica, China, and Great Britain and strong operations in Minnesota and Utah, ATL delivers scale, flexibility, and supply chain resilience. ATL's facilities are equipped to support low-volume prototyping through high-volume production, allowing customers to grow seamlessly. "As a strategic partner, ATL helps turn innovation into reality," said Zane Daggett, vice president of sales. "ATL's focus is enabling customers to improve patient outcomes worldwide."



Since 2001, PDV MedTech, formerly Phoenix DeVentures, has supported more than 600 medical device projects for startups and established global brands, combining product realization expertise with ISO 13485 contract manufacturing. "Medical innovation only reaches patients

when great ideas can be translated into reliable, scalable products,” said Bryant Grigsby, CEO of PDV MedTech. “At PDV MedTech, our role is to help customers bridge that critical gap between design intent and manufacturing reality.”



PDV MedTech's injection molding bridges component manufacturing & finished-device assembly.

As a contract manufacturing partner, PDV translates customer product designs, requirements and specifications into manufacturable medical technologies through a disciplined process that connects engineering, process development, quality systems and production. In-house capabilities include manufacturing engineering, injection molding, 3D printing, mold tool fabrication, cleanroom assembly, packaging and document control support. That integrated scope matters because medical innovation rarely advances on design alone. Innovators need partners who can help preserve design intent, reduce production risk, and scale efficiently as demand grows.

PDV's footprint includes its Utah facility alongside sites in California, Colorado and Texas, with production capacity ranging from dozens to millions of units annually. Following its 2025 acquisition by INDO-MIM, PDV MedTech has expanded its capabilities and global reach with strategic offshore resources in India and Mexico, while staying rooted in a hands-on, partnership driven approach dedicated to advancing healthcare innovation and saving lives.



The story of most medical devices begins with an alpha prototype, a rough proof of concept that shows how an idea might work, but doesn't prove it can be manufactured reliably, scaled, or trusted in a clinical setting. That's where Turner Medtech comes in.




Turner MedTech was recently included in the INC.5000 Fastest Growing American Companies & the Utah Business Fast 50.

For example, when an independent inventor brought a stealth-stage clinical device to Turner MedTech, the development process required an immediate balancing act between regulatory strategy, engineering complexity, and speed. While the inventor initially believed the device sat outside FDA reach, regulatory review determined that its interactive role in patient procedures classified it as a medical device. The team adapted by building the product to Class I standards from the start. Embedding design controls, documentation, and testing early on costs relatively little for exempt devices, but it prevents costly redesigns later, leaving formal registration as a flexible business decision.

To accelerate the timeline without sacrificing quality, the team traded against cost, the classic lever in a quality/cost/calendar constraint. The fix: hire an additional engineer to compress the schedule. Turner's existing contract manufacturing infrastructure meant the new engineer could be integrated into the existing project flow immediately, the same process discipline that goes into engineering the device itself extends to how the work is staffed and sequenced.

Moving from alpha to a production-ready beta meant replacing off-the-shelf components with a custom electronics board, shifting the focus to repeatability. By locking in strict user requirements, securing supply chains, and establishing validation testing, the process successfully converted a rough benchmark idea into a highly scalable, commercial product.

Utah is among the eight largest states for manufacturing medical devices. In addition to those mentioned, other Utah-based contract manufacturers include Paragon Medical (Smithfield) and Nuvia (Draper). 



A New Cleanroom

Designed for Modern Sterility Testing Expectations

For over 40 years, Nelson Labs has helped leading medical device and pharmaceutical companies achieve reliable sterility testing results.


The new cleanroom at our global headquarters in Salt Lake City, Utah, was designed for today's rigorous contamination control expectations, driven by EU GMP Annex 1.

Learn more at **nelsonlabs.com**.



Safeguarding Global Health[®]
with every test we complete

Life Sciences meets Quality of Life.



UTAH



LANDMARK APPROVAL



AVLAYAH[™]
(tividenofusp alfa-eknm)

DENALI'S FDA-APPROVED HUNTER SYNDROME TREATMENT


The FDA approval of Denali Therapeutics' AVLAYAH[™] (tividenofusp alfa-eknm) is a landmark moment for families with the rare genetic disease Hunter syndrome and for the field of neuroscience. AVLAYAH is the first FDA-approved biologic designed to cross the blood-brain barrier (BBB), a long-standing scientific challenge.

Children with Hunter syndrome are born missing an enzyme that breaks down harmful waste in the cells, which then builds up throughout the body and brain. Hunter syndrome can lead to loss of speech, hearing, and cognitive abilities. Although enzyme replacement therapy has been available for nearly two decades, it could not cross the BBB and left the neurological manifestations of the disease largely untreated.

Denali set out to change that. AVLAYAH combines the missing enzyme with Denali's proprietary TransportVehicle[™], which is designed to deliver biologics across the BBB.


"AVLAYAH represents the realization of our vision at Denali, which is to overcome the blood-brain barrier and bring transformative medicines to people living with neurodegenerative diseases," said Ryan Watts, PhD, chief executive officer of Denali Therapeutics. "For Hunter syndrome families, AVLAYAH offers new hope. For science, it validates a new approach with potential for other diseases such as Alzheimer's."

In a clinical study, AVLAYAH demonstrated dramatic reductions in cerebrospinal fluid heparan sulfate (CSF HS), a biomarker associated with neurological disease progression in Hunter syndrome, with the majority of patients achieving levels within the range of children without the disease. The most common adverse reaction was infusion-related reactions. The FDA's acceptance of CSF HS as a surrogate endpoint helped to accelerate the approval of AVLAYAH, demonstrating how biomarkers can be integrated into studies to accelerate drug development for neurodegenerative diseases.



"We are at the beginning of a new era of medicine for brain diseases now that we have solved the challenge of the blood-brain barrier."

—Ryan Watts, CEO, Denali Therapeutics 



Recursion TI
Salt Lake City, Utah

INTEGRITY FIRST, COMMITMENT ALWAYS.

We are dedicated to providing modern construction solutions to build and support the innovative needs of Utah's life science community.

GENERAL CONTRACTOR
PRECONSTRUCTION SERVICES
DESIGN BUILD
CONSTRUCTION MANAGEMENT



ENGAGECONTRACTING.COM

TRANSFORMING DRUG DEVELOPMENT

ANIMAL-FREE TESTING

AZUNIC✓



Every year, thousands of drug candidates fail in human clinical trials, not because the science was wrong, but because the model used for testing was. Animal biology is not human biology. More than 90% of drug candidates that enter clinical trials never reach patients, and every one of them looked safe and effective in animals first. Patients, developers, and the broader healthcare system pay the price.

Azunic was founded to change that. Azunic's platform offers a cutting-edge New Approach Methodology (NAM) that combines sophisticated computational modeling and microphysiological systems, such as iPSC-derived organoids, to generate toxicity predictions that are genuinely human-based. The result is a platform that doesn't just reduce reliance on animal testing; it replaces it with something better.

Central to Azunic's approach is the AVOIDOME, a proprietary framework designed to systematically map and anticipate adverse outcomes before they reach the clinic. This positions sponsors to make smarter go/no-go decisions earlier, accelerating Investigational New Drug submissions while protecting patient safety.

"We didn't build Azunic to tweak the existing model; we built it because the existing model is broken," said Jerry Henley, CEO. "Human biology deserves human data."

Headquartered in Utah, Azunic is proud to be part of one of the nation's fastest-growing life sciences ecosystems, contributing to a future where drug development is faster, safer, and more ethical for patients, science, and animals. 





BIOUTAH



**Business
Solutions®**
More savings.
More research.

SCALE SMART. SPEND LESS.

BioUtah members get instant access
to Fortune 500 pricing.

\$8.2M

SAVED BY BIOUTAH
MEMBERS IN 2025

BIOUTAH MEMBER SAVINGS PROGRAM

Serious companies need serious spend reductions—no matter the stage.

Cut your costs with BioUtah's pre-negotiated vendor discounts—no fees, no sourcing hassles, no negotiations.
One vendor discount could pay for your entire BioUtah membership.

BIOUTAH MEMBERS UNLOCK DEEP DISCOUNTS ON:

- Lab Supplies & Equipment
- Compliance, Waste & Regulatory Services
- Shipping, Office & Facility Operations
- HR, Benefits & Biotech Benchmarking

REAL MEMBERS REAL SAVINGS

GROWTH-STAGE
BIOTECH

\$176K
SAVED

EARLY-STAGE
LABORATORY

\$52K
SAVED

COMMERCIAL
MANUFACTURER

\$97K
SAVED

READY TO SAVE?

Book a 15-minute savings consultation.

We'll help you identify which BBS vendors can generate savings that potentially cover your membership and extend your runway.

For more information or to join BioUtah, scan the QR code, email or call us.

✉ bbs@bioutah.org

☎ 801.867.4061



bioutah.org/bio-business-solutions



UTAH'S BUILDING TOMORROW INCUBATORS



CENTER FOR
MEDICAL INNOVATION
UNIVERSITY OF UTAH



James LeVoy Sorenson Center for Medical Innovation on University of Utah campus.

Bringing a medical technology to market is a big endeavor. Startups face scattered resources, complex regulations, and limited access to clinical insight. Without the right support, even the very best ideas can stall before reaching patients. The startup incubators at University of Utah's Center for Medical Innovation (CMI) position companies to succeed in a thriving ecosystem. CMI provides furnished offices and advanced prototyping tools so teams can design, build, and validate in one location, including device testing and training in the ASCENT Surgical Lab and ISO 8-compliant cleanroom.

What sets CMI apart is the support system. Startups collaborate with engineers, clinicians, regulatory experts, and other founders who help refine ideas, navigate U.S. FDA regulatory pathways, and accelerate development. This integrated approach helps businesses move from concept to commercialization with confidence. CMI's inaugural incubator community includes Australis Scientific, Bloom Surgical, Fusetec, Medicell Healthcare, Microvascular Therapeutics, and Purgo Scientific. Bloom Surgical began its journey in CMI's Bench to Bedside program, growing from a winning student project into a scaling company.

By uniting expertise, infrastructure, and community, CMI's incubators provide the foundation startups need to grow and ultimately improve patient care in Utah and worldwide.



Portal Innovations will provide lab space as shown at its Woodbine Labs facility in Salt Lake City.

Scientific breakthroughs require more than laboratory space to succeed. Founders need access to infrastructure, expertise, capital, and a community that can help transform research into real-world impact. Portal Innovations was founded to provide that support. Headquartered in Chicago at Fulton Labs, Portal helps science-driven entrepreneurs build and scale companies through specialized laboratory environments, operational expertise, strategic partnerships, and commercialization-focused programming. A key part of this mission is Powered by Portal, a platform that partners with universities, healthcare systems, research institutions,

and economic development organizations to design, launch, and operate innovation hubs across the country.

Portal is now bringing this model to Utah through Portal at Woodbine Labs, a 30,000-sq-ft science hub in Salt Lake City expected to open in early 2027. By partnering with leading institutions such as BYU, the University of Utah, and Huntsman Cancer Institute, Portal is committed to strengthening Utah's growing life sciences ecosystem and helping founders build and scale companies across the Mountain West.

Other Portal locations include the UChicago Science Incubator in Chicago, the New Jersey Innovation Hub in New Brunswick, and Ocean State Labs in Providence, where Portal provides laboratory infrastructure, operational expertise, and founder-focused programming to help startups grow. Since 2020, Portal's ecosystems have helped startups secure over \$1B in funding.

"We're eager to bring this winning playbook to med tech, diagnostic, and biotech visionaries in Utah," said John Flavin, CEO of Portal Innovations.




Atwood Innovation Plaza opens shared lab space with leasable benches and private labs.

Atwood Innovation Plaza (AIP) at Utah Tech University in St. George, Utah, recently brought a fully equipped wet lab incubator to southern Utah's biotech community.



BiInnovations
G A T E W A Y



BiG resident company, Fluidx, presents topline results from the GPX IDE Pivotal Trial at SIR 2026.

The laboratory offers over 2,000 square feet of move-in-ready laboratory space, including dedicated microbiology and molecular biology lab space, with both private leasable laboratory space and shared bench top space available. This purpose-built environment gives incoming companies a meaningful head start in the life sciences sector.

The facility provides shared access to professional-grade equipment spanning genomic sequencing, cell culture, microscopy, sterilization, and molecular analysis—everything an emerging life sciences company needs without the capital burden of building out a proprietary laboratory. The space is well suited for companies working in genomics, pharmaceutical research, biomedical innovation, precision medicine, and related fields. At 300 miles from the nearest comparable facility, this laboratory fills a critical gap across the entire southwest region.

In addition to laboratory space and shared equipment, tenants gain access to a proven entrepreneurial ecosystem. Since its founding, AIP has supported over 2,600 business consultations, launched 181 businesses, and assisted in filing over 330 patent applications across the region. Startups within the space will plug directly into an established mentor network.

The laboratory will also serve as home to the BioLaunch Program, a National Science Foundation-funded biotech entrepreneurship curriculum for Utah Tech undergraduates. Utah Tech is further strengthening the regional talent pipeline with the launch of a new master's degree in genomics beginning this fall. This blend of academic programming and startup ecosystem will cultivate natural opportunities for collaboration and talent acquisition.

BiInnovations Gateway (BiG) is a life sciences incubator dedicated to accelerating the growth of early-stage companies by providing access to the specialized equipment and facilities essential for research, product development, and commercialization. These resources give startups the time and space to navigate critical challenges, including regulatory hurdles associated with securing Investigational Device Exemptions (IDEs) and Investigational New Drug (IND) approvals. As a result, multiple resident companies have advanced to clinical trials following receipt of their IDE or IND authorization.

What sets BiG apart is its integration of startup incubation with the Granite School District's Career & Technical Education system. This unique model combines innovation and workforce development by providing students with hands-on, practical experience alongside entrepreneurs and industry professionals. Students gain valuable skills through direct exposure to real-world laboratory operations, quality systems, and regulatory processes while supporting Utah's growing life sciences ecosystem. By fostering both company success and talent development, BiG is helping build the next generation of life sciences innovators and strengthening Utah's future workforce.



Daniel Rodriguez-Granrose at Altitude Lab's 2026 Demo Day.

Founded in 2020 by Recursion, Altitude Lab has emerged as one of the Mountain West's leading engines for biotech entrepreneurship and a nationally recognized model for early-stage life science innovation. Headquartered in Salt Lake City, Altitude Lab was created to address one of biotechnology's greatest challenges: helping scientific founders transform breakthrough discoveries into venture-backed companies. Altitude Lab combines laboratory infrastructure with hands-on commercialization support, executive mentorship, direct access to strategic pharma for partnering and business development discussions, and a national network of more than 200 investors, helping founders navigate the journey from scientific discovery to venture-backed company.

Despite one of the most challenging biotech fundraising environments in recent years, Altitude Lab portfolio companies have collectively raised more than \$205M in capital. In 2025, resident companies including Peel Therapeutics and Rebel Medicine closed Series A financings, while companies such as Leash Biosciences, Sether Therapeutics, and 3Helix advanced novel technologies and expanded partnerships with leading pharmaceutical companies. Since its founding, Altitude Lab has launched more than 41 biotech startups and continues to accelerate the commercialization of breakthrough science across therapeutics, diagnostics, and enabling technologies. By connecting entrepreneurs with investors, experienced operators, and industry partners, Altitude Lab is helping establish Utah as one of the nation's fastest-growing hubs for biotech innovation and company creation.



UVB Capital offers companies access to expertise such as David Bearss, PhD, a UVB incubator co-founder.

UVB Capital has launched a new incubator in Lehi, Utah, designed to give seed- and early-stage life sciences companies the space, support, and specialized expertise they need to grow. The facility offers an environment built specifically for founders navigating affordability and the demanding path from discovery to market. With more than 100 cubicles, the space accommodates lean founding teams and growing companies alike, giving them a professional home base without the overhead that often burdens young ventures.

Beyond the workspace, the incubator's real differentiator is access to deep domain expertise including Dr. David Bearss, a co-founder of the UVB Incubator. Resident companies can tap into guidance across the areas that matter most in bringing a therapeutic to life: drug discovery, clinical development, regulatory strategy, and manufacturing. This hands-on access to seasoned specialists helps founders avoid costly missteps, accelerate their timelines, and make smarter decisions at every stage.

By combining affordable, flexible office space with practical, industry-specific mentorship, UVB Capital aims to lower the barriers that so often stall promising early-stage companies. The result is a community where innovation can take root and scale. 



Convergence Hall
The Point, Draper, UT



Architects and lab planners dedicated to planning, programming, and designing spaces for *Utah's thriving life science innovation community.*

Our team provides expertise across a range of facility types including:

- Flexible and efficient laboratories
- Collaboration-driven workplace design
- Innovative R&D spaces supporting cutting-edge technologies
- Turnkey incubator facilities for emerging entrepreneurs
- Biomedical manufacturing facilities
- Cleanroom design
- Master planning and visioning for strategic growth

Clients trust us to design cost-effective, high-performance facilities tailored to their unique needs, with the versatility to adapt to future innovation in a rapidly evolving industry.

Industry Collaboration



WHERE LIFE SCIENCES



IS HAPPENING



UTAH'S LIFE SCIENCES
GEOGRAPHIC DISTRIBUTION



1

CACHE / WEBER COUNTIES:

COMPANIES INCLUDE:*

- CYTIVA
- THERMO FISHER
- ELITECH/BRUKER
- FRESENIUS MEDICAL
- IBEX PRECLINICAL RESEARCH
- PARAGON MEDICAL
- QUANSYS BIOSCIENCES
- SCYTEK LABORATORIES

2

UTAH COUNTY:


COMPANIES
INCLUDE:*

- ATL MEDICAL
- BLUE SKY BIOLABS
- CANARY SPEECH
- DYMICRON
- HALIA THERAPEUTICS
- LIGER MEDICAL
- NEXUS SPINE
- OWLET
- PHOTOPHARMICS
- TURNER MEDTECH

DEVELOPMENT[S]:

- HUNTSMAN CANCER INSTITUTE VINEYARD CAMPUS 🏗️
- TRAVERSE MOUNTAIN
- UVB CAPITAL 🏗️

SALT LAKE COUNTY:



3

SOUTHERN UTAH:

COMPANIES INCLUDE:* DEVELOPMENT[S]:

- ANBEX
- BIOFI
- CATH TIP
- DESERET LABS
- DUCT-AID
- FORWARD MOTION
- ORION INNOVATIONS
- ATWOOD INNOVATION PLAZA 🏠
- TECH RIDGE 🚧

4

SALT LAKE - NORTHWEST:

COMPANIES INCLUDE:* DEVELOPMENT[S]:

- BD
- BIOMERICS
- BIOMÉRIEUX
- DENALI THERAPEUTICS
- DISCGENICS
- GE HEALTHCARE
- MYRIAD GENETICS
- TEVA PHARMACEUTICALS
- INTERNATIONAL CENTER
- UTAH INLAND PORT

5

SALT LAKE - GRANARY / DOWNTOWN:

COMPANIES
INCLUDE:*

- CARTERRA
- EPI TEL
- KOLOSIS BIO
- RECURSION
- SEEK LABS
- WASATCH HEALTH

DEVELOPMENT[S]:

- ALTITUDE LABS 🏠
- BIO INNOVATIONS GATEWAY 🏠
- PORTAL INNOVATIONS 🏠
- THE GATEWAY

6

SALT LAKE - RESEARCH PARK AREA:

COMPANIES
INCLUDE:*

- ARUP LABORATORIES
- BIOMÉRIEUX
- BIOS
- BLACKROCK NEUROTECH
- RENALYTIX
- SERA PROGNOSTICS

DEVELOPMENT[S]:

- CENTER FOR MEDICAL INNOVATION 🏠
- RESEARCH PARK

7

SALT LAKE - WESTERN CORRIDOR:

COMPANIES
INCLUDE:*

- AuST MANUFACTURING
- EVOQ
- GLOBALMED LOGISTIX
- NUSANO
- POLARITYTE
- RATIO THERAPEUTICS
- SCIENTIA VASCULAR
- SINTX
- STRYKER
- VAREX IMAGING

DEVELOPMENT[S]:

- MEDICAL INNOVATION TECHNOLOGY RESEARCH CAMPUS

8

SALT LAKE - MIDVALLEY:

COMPANIES INCLUDE:*

- CLENE NANOMEDICINE
- ENABLECV
- LABORIE
- NELSON LABS
- ROUTE 92 MEDICAL
- UTAH MEDICAL PRODUCTS

9

SALT LAKE - SOUTH VALLEY:

COMPANIES
INCLUDE:*

- BD
- CANYON LABS
- EDWARDS LIFESCIENCES
- MERIT MEDICAL
- ORTHO DEVELOPMENT
- RENEGADE MEDICAL
- SPORTS MEDICINE RESEARCH & TESTING LAB
- ULTRADENT PRODUCTS
- XENTER

DEVELOPMENT[S]:

- THE POINT 🚧

Data Provided by:

CHRIS
KIRK
Commercial Real Estate

@ Colliers

PRICE
REAL ESTATE

LEGEND:

🏠 = Incubator

🚧 = Under Development

*Sample of companies in area. Not a full list.

WHAT'S NEW

UTAH'S LIFE SCIENCES LATEST SCOOP

2026 EDITION



Ratio Therapeutics is a clinical-stage pharmaceutical company developing next-generation precision radiopharmaceuticals for patients with solid tumors. Through its proprietary Macropa™ and Trillium™ platforms and systematic engineering approaches, Ratio is advancing targeted radiopharmaceuticals designed to enhance tumor uptake, retention, and therapeutic impact. Its lead clinical program is a FAP-targeted alpha radiotherapeutic for patients with relapsed or refractory soft tissue sarcomas.



Ratio's facility at Lake Park in West Valley City is nearing completion.

As radiopharmaceuticals gain momentum across oncology, delivering these therapies to patients requires more than clinical innovation. The field is constrained by isotope availability, short half-lives, and the need for tightly synchronized manufacturing and logistics. Reliable production, rigorous quality control, and just-in-time distribution are now central determinants of clinical and

commercial success. Utah has emerged as an important location in meeting these demands.

The Salt Lake City region combines international air and ground transportation links, an experienced life sciences workforce, and proximity to growing isotope supply and radiopharmacy networks, making it well suited to the complex requirements of radiopharmaceutical development and manufacturing. Strong support from state and local officials, together with Ratio's developer and partner, the Wasatch Group, has further reinforced the company's decision to invest in Utah.

Ratio's expansion reflects a belief that advancing innovative cancer therapies requires not only strong science, but also the reliable manufacturing and operational capabilities needed to bring these therapies to patients consistently and at scale. Utah offers the complete package.



Summit Bioservices is a U.S.-based provider of GMP-compliant storage, logistics, and laboratory support services for the life sciences, biotechnology, pharmaceutical, medical device, and healthcare industries. Summit's 35,000-square-foot facility in West Valley City, Utah, offers secure ambient, refrigerated (2–8°C), and frozen (–20°C and –80°C) storage, supported by validated equipment, continuous environmental monitoring, backup power systems, and robust quality systems.



Summit facility at the Lake Park development in West Valley City.

The company's services include inventory management, bulk storage, dispensing, labeling, temperature-controlled shipping, stability storage, and customized supply chain solutions. In addition, they support clinical, commercial, and research programs with scalable services designed to maintain product integrity, regulatory compliance, and complete chain of custody. Whether supporting early-stage biotechnology companies or established pharmaceutical manufacturers, Summit's experienced team provides reliable, compliant, and cost-effective storage and logistics services that help accelerate research, development, and commercialization.

GlobalMed
LOGISTIX



When the company set out to expand GlobalMed Logistix's (GMLx) footprint beyond its Atlanta headquarters, they weren't just looking for warehouse space. They were looking for a community. The Salt Lake Valley stood out immediately. It's home to a thriving life sciences ecosystem, the kind of place where medtech innovation happens because talent, infrastructure, and ambition converge. That's exactly the environment orthopedic, spine, cardiovascular, and dental device manufacturers, need from a logistics partner like GMLx.

This October 2026, the company will open a 75,000-square-foot facility in the Raceway Commerce Center in West Valley City, minutes from Salt Lake City

International Airport. The site will support inventory management, order fulfillment, surgical tray and kit assembly, warehousing, reverse logistics, quality control, and tissue storage and distribution. Paired with its East Coast operations, this new bi-coastal footprint sharpens the speed, reliability, and precision of GMLx, bringing them closer to the patients their customers ultimately serve delivering every product to the right place at the right time, every time.



GlobalMed's new distribution center at the Raceway Commerce Center.

Just as important as the location is the community. "GMLx recently became a member of BioUtah," said Patrick Daly, CEO of GMLx. "This membership has connected us to Utah's vibrant life sciences community, allowing us to collaborate, learn, and contribute. Salt Lake City is more than a new hub for us—it is our new home."



Renegade Medical Extrusion was founded with a clear mission: to help medical device innovators bring life-changing technologies to market faster through precision extrusion, technical expertise, and exceptional responsiveness. By combining advanced manufacturing with rapid development timelines, the company partners with customers to solve complex engineering challenges and accelerate innovation from concept to commercialization.






Renegade manufactures a variety of extruded products.

To support that mission, Renegade continues to invest in advanced manufacturing capabilities, including new extrusion lines, taper tubing technology, braided shaft manufacturing, programmable coil forming, and an expanding portfolio of complex extrusion solutions. These investments strengthen Renegade's ability to support the next generation of minimally invasive medical devices with tighter tolerances, faster prototyping, and scalable production.

Utah's unique combination of engineering talent, manufacturing expertise, and entrepreneurial spirit creates an environment where companies like Renegade can grow, invest, and help shape the future of healthcare. The impact of its work extends well beyond manufacturing. Every extrusion produced has the potential to support medical devices that improve patient outcomes through more precise and less invasive procedures. As Renegade continues to expand, they are committed to creating high quality jobs, investing in advanced technologies, and strengthening Utah's position as a leader in life sciences and medical manufacturing excellence.



The outcome of care is often determined before care begins, and for a hundred years, healthcare left that outcome to a piece of paper-thin fabric that opens in

the back. Anyone who has been a patient understands this all too well... patients holding standard gowns closed with one hand, half-answering the doctor's questions because the gown itself had already told them they weren't safe here. That pattern led to the founding of GIV Gowns.



GIV Gowns restore patient confidence & dignity.

GIV designs its gowns starting with what the body and the medical exam actually require, not what a supply catalog offers. The company's proprietary overlapping construction gives medical providers full clinical access while giving patients full coverage, so dignity and efficiency stop competing with each other. From there, they built modular, purpose-built solutions across eleven product lines, each engineered for its exact moment of care instead of forced into one generic shape. Whether patients bring their own gowns or providers supply the gowns, patients feel covered and engage more honestly and better trust the care they are receiving.

Every GIV purchase feeds the GIV Back Initiative, carrying dignity into under served communities worldwide. The company will grow from here, aiming for a global standard in patient trust, built in Utah, worn everywhere.

Blue Sky™
— Bio Labs —



Located in Lehi's Silicon Slopes, at the heart of Utah's rapidly growing biotechnology and life sciences corridor, Blue Sky Bio Labs serves biotechnology developers,

healthcare organizations, and medical professionals through advanced laboratory services and carefully controlled processing of human cell- and tissue-based products.




Blue Sky Bio Labs location in Lehi, Utah.

Its ISO 5 and ISO 7 laboratory capabilities include research and development, bioanalytical testing, product characterization, cleanroom processing, cryogenic storage, protocol development, and regulatory consulting. Blue Sky Bio Labs supports drugs, biologics, medical devices, cellular therapies, and other emerging healthcare technologies from early development through commercialization.

Blue Sky Bio Labs works with qualified medical providers by offering scientific expertise, controlled processing, quality testing, and documentation for certain human cell- and tissue-based products. These activities are conducted under an established quality system and according to the requirements applicable to each product, process, and intended use. The company does not make treatment decisions; instead, it provides the laboratory infrastructure and technical support that help medical professionals responsibly serve their patients.

Blue Sky's commitment to scientific rigor, responsible innovation, and collaboration is helping strengthen Utah's biotechnology sector while supporting the careful advancement of regenerative medicine and other promising healthcare solutions.



Route 92 Medical is a privately held medical technology company focused on improving outcomes for patients experiencing neurovascular conditions, such as strokes. The company recently relocated its corporate headquarters to West Jordan, Utah.

"Choosing West Jordan was a strategic decision driven by Utah's exceptional talent pool and its reputation as a leader in innovation," said Tony Chou, MD, founder and CEO at Route 92 Medical.

The headquarters relocation in March 2026 added to the large-scale manufacturing and training facility opened in 2022 and capped a year of momentum. The company raised \$50 million in growth financing, completed SUMMIT MAX, a randomized controlled trial evaluating a new reperfusion catheter system, secured new regulatory approvals, and entered the Canadian market.



Associates assemble the highly technical Route 92 catheters for neurovascular intervention.

Building on that foundation, Route 92 Medical launched SUMMIT RISE, a 500-patient, multi-center real-world study assessing the performance of its reperfusion systems across diverse stroke scenarios and vessel sizes. With its West Jordan location, Route 92 Medical continues to influence an actively growing section of Utah's neurointervention ecosystem, bringing high-skill jobs, clinical research, and stroke care technology to the state.





As one of the nation's fastest growing life sciences and biotech communities, Salt Lake City is emerging as a world-class hub for innovation. With a bold vision and transformative ideas, we are paving the way for breakthroughs that will shape the future.

TECHLAKECITY.SLC.GOV



DEPARTMENT of
ECONOMIC
DEVELOPMENT



HiveCast spotlights the people building Utah's life sciences ecosystem, and the real-world impact their work has on patients and communities, making Utah *the place* for healthcare innovation.



biohive.com/hivecast/

FROM MYSTERY ILLNESS TO DIAGNOSIS:

WHY LABORATORY-DEVELOPED TESTS MATTER



Misty Segrest: diagnosed with indolent systemic mastocytosis after a decade-long search for relief.

Misty Segrest spent more than a decade searching for answers as strange, painful bumps spread across her body. What began as a few small red dots on one finger multiplied. She said the itching was relentless. “The welts felt like a million ants crawling across my skin,” Segrest said. Despite multiple doctor visits and allergy medications, Segrest found little relief. Her experience is common for patients with systemic mastocytosis (SM), a complex disorder that occurs when mast cells, a type of white blood cell, accumulate throughout the body. When activated, the cells can trigger a range of symptoms, such as skin rashes, gastrointestinal distress, heart palpitations, fatigue, and even anaphylaxis.

“Patients don’t present with one clear problem,” said Tracy George, MD, ARUP Laboratories’ chief scientific officer and president of the Innovation Business Unit. “They come in with a wide constellation of symptoms that cross many different specialties.” On average, it takes nearly 10 years to diagnose SM. For Segrest, the breakthrough came after a referral to Huntsman Cancer Institute, where specialized laboratory testing was ordered. That testing was performed at ARUP and identified a key genetic mutation, *KIT*D816V, associated with the disease. With that answer, she finally had a clear path forward.

“It’s one pill a day,” Segrest said. “And as long as the medication works for me, I can live a more normal life.”

The test that finally provided a diagnosis and eventually relief was one developed at ARUP as a laboratory-developed test (LDT). “If you know the exact mutation, you can predict which therapy is going to work,” George said. Segrest’s story highlights the critical role of LDTs, which are designed and performed within a single clinical laboratory. For patients with SM and other difficult-to-diagnose or rare diseases, LDTs are often the only way to uncover underlying causes and guide treatment.



Left: Segrest’s back inflamed with red, itchy bumps. Right: Segrest’s back after diagnosis and treatment.

As LDTs have evolved in complexity, so has the conversation on how to regulate them. In May 2026, Rep. Neal Dunn, (R-FL), who is a physician, introduced the Enhancing Clinical Laboratory Innovation and Access Act of 2026 (Enhancing CLIA Act). The bill represents the first

legislative effort to address LDT oversight following the 2025 court decision in the American Clinical Laboratory Association v. the Food and Drug Administration (FDA), which vacated the FDA's final rule that would have regulated LDTs as medical devices, reaffirming the Clinical Laboratory Improvement Amendments (CLIA) as the primary regulatory authority. ARUP applauded the court's decision.



Tracy George, MD, CSO & president of the Innovation Business Unit at ARUP, examines slides using the microscope in her office.

The proposed legislation builds on the CLIA framework and has the potential to strengthen both innovation and transparency in laboratory medicine. "This is an important proposal that will hopefully spark crucial conversations across the clinical laboratory community," said Jonathan Genzen, MD, PhD, MBA, chief medical officer and senior director of government affairs at ARUP. "I'm personally grateful that a physician member of Congress introduced this bill, as it reinforces the importance of quality, transparency, and innovation in laboratory tests used for patient care."

The bill would establish a public database of LDT information, require reporting of serious test errors, and allow optional third-party review to confirm test validity. Clinical laboratories are central to modern medicine, helping diagnose disease, guide treatment, and advance precision care. Thoughtful oversight is key to ensuring patients benefit from these innovations.

Today, Segrest said, her symptoms are under control, and the uncertainty that once defined her life is gone. "I cannot express enough gratitude," she said. "My life is so much better." 



Jonathan Genzen, MD, PhD, MBA, ARUP's CMO & senior director of government affairs.

**"I CANNOT EXPRESS
ENOUGH GRATITUDE.
MY LIFE IS SO MUCH BETTER."**

— Misty Segrest





Manufacturing for Life.®



ATL provides industry-leading end-to-end medical device design, development, and manufacturing services, supporting OEMs from early concept through full-scale production and beyond.

Cardiovascular / Electrophysiology / Electrosurgical / Endoscopic Imaging

ATLMedical.com



BIOUTAH

LIFE SCIENCES AWARDS 2025

Utah's life sciences industry is recognized as a leader in healthcare innovation and a force for economic growth. BioUtah holds an annual award ceremony to celebrate the distinguished service, notable achievements, and outstanding contributions of the change makers that are shaping the sector and building its future.

BioUtah also holds an annual Shark Tank-style Pitch Competition where panels of expert judges award prizes to medical device, diagnostic, biotechnology, and digital health startups.

"Our award winners exemplify the vision, pioneering spirit, and leadership of Utah's life sciences community. They deserve a big round of applause for pushing the boundaries of science and technology to advance health and wellness."

— Kelvyn Cullimore
President and CEO,
BioUtah



LIFETIME ACHIEVEMENT

Wesley Sundquist, PhD, Samuels

Professor and chair of the
Department of Biochemistry at the

University of Utah, was recognized

for his research on human immunodeficiency virus (HIV) assembly and replication, which led to the U.S. Food and Drug Administration's approval of Lenacapavir in June 2025, a drug Gilead Sciences created using his findings, for HIV prevention.



EXECUTIVE OF THE YEAR

Fred Lampropoulos, executive
chairman of Merit Medical

Systems, was recognized for his
outstanding leadership and vision

in founding and guiding Merit Medical Systems with a steady hand since its formation in 1987. While headquartered in South Jordan, Utah, Lampropoulos has presided over Merit's worldwide expansion with operations in Ireland, Mexico, Singapore, the Netherlands, France, Texas and Virginia.

RECOGNIZING EXCEPTIONAL LEADERSHIP AND SERVICE



ENTREPRENEUR OF THE YEAR

Shawn Fojtik, CEO of Distal Access, was recognized for his bold, inspiring can-do spirit and constant drive for innovation to improve patients' lives, resulting in 100+ combined issued and pending patents and the founding of multiple companies, including Axiom, CIRCA, Distal Access, Fluidx, Pinyons, PolyEmbo, Transit, and Ventiv, and more.



INNOVATION IMPACT

Nusano was recognized for its breakthrough production platform and design that allows for the simultaneous creation of a wide variety of radioisotopes, not possible with current methods. Nusano's technology will stabilize supply chains, increase national security, and enable next-gen innovations in fields ranging from healthcare to nuclear energy.



FRIEND OF INDUSTRY

Taylor Randall, president of the University of Utah, was recognized for his partnership and support for Utah's life sciences industry, including development of the Center for Medical Innovation, and initiatives such as the Life Sciences Workforce Initiative to ensure the state has a pipeline of highly-skilled workers.



ENTREPRENEUR & INVESTOR LIFE SCIENCES SUMMIT

2026 "SHARK TANK" WINNERS

Four Utah companies were honored as winners of the Shark Tank-style pitch competition at BioUtah's 2026 E&I Summit, sponsored by Wilson Sonini.

These standout startups each took home a \$4,000 grand prize and a one-year membership in BioUtah: **Azunic AI** for Therapeutics Pharmaceuticals; **Freyya** and **Purgo Scientific** for Medical Devices and Diagnostics; and **Intactis Bio** for Digital Health and Biotechnology.

MERIT MEDICAL NAMED 'INTERNATIONAL BUSINESS OF THE YEAR' AT ONE UTAH SUMMIT

At the 2026 One Utah Summit, the World Trade Center's International Business of the Year award recognized Merit Medical Systems—a company that has elevated Utah's global presence through its exceptional global business efforts.

Growth Starts with yo(u)

FROM DISCOVERY TO DELIVERY.



Expanding Opportunities Across Utah

UIPA has 16 Project Areas across the state of Utah, with ideal location opportunities both on and off the Wasatch Front.



Incentives Aligned to Life Sciences

UIPA and state partners offer unique post-performance financial incentives that are stackable, crafting robust financial support for expansion in Utah.



Support for Logistics Infrastructure

UIPA works with local communities to make meaningful investments in logistics infrastructure that will directly benefit Life Science industries.

MOVING UTAH FORWARD

For more information, contact:
Scott Welford
scottwelford@utah.gov
p 801.538.8950



**UTAH INLAND
PORT AUTHORITY**

Moving Utah Forward

LOCAL TO GLOBAL



ANOTHER UTAH SUCCESS STORY

Before Nelson Labs became a global leader in microbiological and analytical chemistry testing for healthcare products, it was a small laboratory built on a Utah family's belief in the importance and impact of good science. The company took shape in the years following the 1976 Medical Device Amendments, which created a need for testing laboratories that could support device manufacturers working under increased regulatory oversight.

Jerry Nelson, PhD, had years of experience in research and commercial laboratories, especially with testing related to endotoxins. He and his wife, Lynda, saw an opportunity to help manufacturers meet the new regulatory expectations. In 1985, they mortgaged their home to lease a one-room facility in the University of Utah's Research Park and, together with a small team and a handful of microbiology services, set out to help medical device manufacturers navigate the changing landscape.

In the company's early years, a gold paperclip was attached to every completed report before it was sent to the customer. The paperclip came to represent more than just a finished study. It signaled the careful way in which the work had been performed. This commitment to scientific rigor and accuracy came to be known among employees and customers as the Nelson Labs "gold standard." That standard



Above Right: Dr. Jerry Nelson at the construction site of Nelson Labs' first building.

was shaped by Jerry Nelson's belief that scientists should understand not only what they were doing but why they were doing it. He encouraged curiosity, critical thinking, and disciplined investigation.

Under the leadership of Jeffery Nelson, Jerry and Lynda's son, the company continued to grow as a trusted scientific partner to healthcare companies around the world. In 2016, Nelson Labs was acquired by Sterigenics International, from which the parent company Sotera Health was later established. Today, as part of Sotera Health, Nelson Labs operates a global network of laboratories that support the development of medical devices, pharmaceuticals, biologics, tissue-based products, and combination products. Additionally, the company's scientists regularly collaborate with regulators, standards



organizations, and manufacturers around the world to address emerging scientific and regulatory challenges.

"Our responsibility is bigger than generating data," said Thor Rollins, a senior leader with 24 years at Nelson Labs. "Our role is to apply science, experience, and sound judgment to help customers make confident decisions that ultimately impact patient safety."

To meet the increasing need resulting from regulatory expectations, unexpected results, risk assessments, and testing strategy decisions, Nelson Labs established its Expert Advisory Services, providing direct access to experienced scientists who could help interpret findings, navigate uncertainty, and make informed decisions. The later addition of Regulatory Compliance Associates further expanded that model by bringing together scientific and regulatory expertise to support customers throughout the product lifecycle.

The critical role Nelson Labs had played as a trusted partner to healthcare companies became particularly visible during the COVID-19 pandemic. As global demand for personal protective equipment surged, manufacturers around the world turned to Nelson Labs to help test masks, gowns, respirators, and other critical products to support their expedited path to market. The unprecedented volume of testing demonstrated not only the company's technical capabilities, but also its ability to rise to challenges of enormous demand and global impact.



Celebrating its 40th anniversary, Nelson Labs has evolved from a one-room laboratory into a globally recognized scientific organization of over 1,000 employees with experts who help shape industry standards, guide regulatory and scientific decision-making, and support healthcare innovation worldwide.





Blue Sky™ – Bio Labs –

Unlock Precision. Accelerate Discovery.

Partner with Utah's premier biologics laboratory for research, testing, and regulatory success.

Scientific Precision. Customized Support.

Located in the heart of Utah's biotech corridor, Blue Sky Bio Labs is a cutting-edge facility specializing in:

- ✓ R&D and formulation for drugs, biologics, and cellular therapies
- ✓ Analytical testing for purity, potency, and characterization
- ✓ Contract lab services supporting end-to-end product development
- ✓ Regulatory consulting for FDA/EMA submissions: BLA, IND, NDA, ANDA

We offer ISO 5, ISO 7, and ISO 8 certified cleanrooms and tailored solutions to support therapeutic innovation. Our lab infrastructure includes cryogenic storage, HPLC/GC systems, and sterile cleanroom environments built for compliance with FDA 21 CFR, GLP, and GMP standards.

**Visit Our Lab In Silicon Slopes And
Experience The Future Of Biotech
Collaboration.**



LEADING WITH PURPOSE

MEET MARTHA ARONSON,
MERIT'S NEW CEO



The Merit Medical mission is clear: understand the needs of physicians and patients, innovate with purpose, and deliver products that help improve care around the world. For Martha Aronson, Merit's new president and CEO, that mission reflects the purpose that has guided her career in healthcare.

Aronson joined Merit in October of 2025 with extensive experience leading growth, advancing innovation, and improving operational performance. Throughout her career, she has held leadership roles at global healthcare organizations, including Medtronic, Hill-Rom, and Ecolab. She has also served on public, private, and nonprofit boards, including CONMED Corporation, Cardiovascular Systems, Clinical Innovations, and Hutchinson Technologies. Together, these experiences have shaped her broad perspective on how companies grow, adapt, and create long-term value.

When she stepped into the role of president and CEO, Aronson's priority was not to announce sweeping changes, but to listen and learn. During her first 100 days, she traveled across the organization, connecting with employees from different functions, geographies,

and cultures. She also spent time with customers to hear firsthand how Merit products support clinical care, what physicians and healthcare teams need most, and where the company can further enhance service, strengthen partnerships, and develop new solutions. Throughout these conversations, she asked the same two questions: What is Merit doing well? And what could we do better?

These answers reinforced what makes Merit unique: a talented team, deep technical expertise, and a shared commitment to serving physicians, hospitals, and the people who rely on Merit products every day. Employees expressed a desire to build on the company's foundation while strengthening communication, collaboration, and alignment across teams. During her visits, Aronson was impressed by the dedication of employees and the practical, customer-focused mindset that defines the company's approach to healthcare.

That collaborative spirit also shapes her leadership philosophy. She believes organizations perform best when individuals are empowered to share ideas, challenge assumptions, and contribute their expertise.



By encouraging open dialogue, accountability, and healthy debate, she seeks to create an environment where diverse perspectives lead to better decisions. In her view, meaningful progress happens when talented people work together toward a shared goal.

Looking ahead, Aronson sees significant opportunity for Merit to address real clinical challenges by staying close to customers and understanding the evolving needs of healthcare systems worldwide. By maintaining these connections, Merit can continue developing technologies that streamline procedures, improve efficiency, and help physicians deliver exceptional care.

Growth remains an important part of that vision. Recent investments, including the opening of a new distribution center at the company's South Jordan headquarters and Merit's acquisition of View Point Medical, demonstrate Merit's commitment to strengthening service to customers. Aronson views these investments as important steps in the infrastructure, capabilities, and partnerships needed to support the company's future.

Merit's legacy, mission-driven culture, and deep Utah roots remain central to its identity. Over the years, the company has helped position Utah as a globally recognized center for life sciences and medical technology. Aronson has come to appreciate the connected nature of this community, where businesses, healthcare providers, legislators, and industry leaders collaborate to advance healthcare worldwide. Merit benefits from this ecosystem while also contributing to its strength through investment, job creation, and industry leadership.

As the company enters its next chapter, Aronson's goal is to build upon Merit's strong legacy while guiding continued progress with clarity, discipline, and purpose. Supported by talented employees, a culture of innovation, and a commitment to meeting the needs of healthcare providers, Merit is well positioned to expand its impact and continue improving lives around the world. 



IN PARTNERSHIP WITH



BIOUTAH
UTAH'S INDEPENDENT LIFE SCIENCE ASSOCIATION

BUILT FOR BIOTECH. BACKED BY SAVINGS.

Exclusively for
members of BioUtah

Achieve group-level pricing and benefits built for Utah's life science workforce.

✓ Startup-to-IPO Strategic
Benefits Program

✓ Analytics & Cost
Insights

✓ Predictable, Fully Insured Premiums,
No Small Group Volatility

✓ Retention Infrastructure That
Reduces Turnover Costs

✓ ERISA, ACA & DOL Risk
Managed On Your Behalf

✓ Benefits Strategy Tied to
Growth Stage, Not Guesswork

100,000
Employer Clients Nationally

25+ Years
Benefits & HR Expertise

SOC-2
Certified for Security & Privacy

MORE SCALABLE SOLUTIONS THAT POWER BUSINESSES

Employee Benefits

Human Resource Consulting

Property & Casualty

Request a Rate & Risk Comparison Today!

Christine Mosby | 801.322.9411 | christine.mosby@onedigital.com
calendly.com/christine-mosby-onedigital/30min





A PURE PLAY STORY



HOW KOLOSIS IS BUILDING A BIOLOGICS POWERHOUSE

APEXecm allogenic matrix for high-risk incisions.



Kolosis bone graft for spinal fusion procedures.

When a surgeon performs a spinal fusion, the attention naturally flows to instrumentation, navigation systems, robotics, and implants—where most of the revenue is captured. But bone graft biologics, the biomaterials used to grow and fuse bone, often represent 20% of the implant revenue and are critical to patient outcomes. These biomaterials demand a different skill set than other implants: deep scientific understanding, nuanced clinical messaging, and a sales approach that communicates tissue engineering complexity. This gap—hardware-focused corporations lacking focus and commitment to bone biologics—represents a genuine market opportunity. Kolosis BIO, a Utah company founded in 2020, set out to fill this gap and is now emerging as a market force.

Collin Begley, founder and CEO, spent over 20 years in some of the medical device industry's largest companies, building expertise in biologics marketing and science. His cousin Keegan Begley brought spine sales leadership and a proven track record building independent distributor networks. In 2020, amid the pandemic, they founded and launched their pure-play biologics company to address this market inefficiency and structured it around a simple truth—the sales rep is the most important customer.

Their first success was securing a strategic partnership with MTF Biologics, the world's largest human tissue processor. Kolosis wanted to focus on allograft materials—deceased donor tissue carefully processed to preserve key structures and growth factors that promote bone healing in patients. MTF brought contracting relationships with GPOs and health systems at scale and clinical credibility while Kolosis became the commercial engine: defining market needs and product portfolio, investing in the science that sets those technologies apart, building brand presence, and running an independent sales organization built on loyalty, responsiveness, and support. Unlike large corporations that view sales reps as cost centers to optimize, Kolosis made the sales rep the center of its universe.

And success for Kolosis quickly followed. From a two-person idea in 2020, Kolosis delivered \$58M in revenue in 2025 and projects to approach \$75M in 2026. Its independent sales channel has scaled to approximately 500, and Kolosis also secured a sales agency relationship with Medtronic, allowing its technologies to reach the world's largest spine and biologics sales force and the patients they serve. Utah proved to be the ideal launchpad. Kolosis established its headquarters in downtown Salt Lake City's historic Rio Grande district, anchoring the company in a state whose life sciences ecosystem offered both cost advantages versus coastal biotech hubs and a strong talent pipeline. Early on, Kolosis built an internship program recruiting from the University of Utah and leveraged the state's strong ecosystem support for medtech entrepreneurs.

Today, Kolosis's portfolio has expanded beyond spine and orthopedics into cardiac surgery, with ATLAS, a bone graft designed to facilitate sternum healing, and IKON, an allograft extracellular matrix for soft tissue repair. In spine and orthopedics, the company has strengthened its offerings to include DBX Putty, DBX Fiber, and Summit Matrix, a ceramic synthetic graft with an engineered nano-surface structure.



Kolosis acquired DBX brand rights in 2025.

The recent launch of APEXecm exemplifies Kolosis's evolution. APEXecm is a novel graft solution designed for surgeons managing high-risk surgical patients—those with conditions predisposing them to infection and poor wound healing. Unlike Kolosis's partnered portfolio, APEXecm is proprietary to Kolosis, enabling direct relationships with health systems, internal capabilities like billing, shipping, and collections, and margin expansion on a product line the company controls end-to-end. Importantly, this infrastructure positions Kolosis to build and scale future proprietary products.

Five years in, Kolosis has proved its founding thesis: a nimble, focused market player with best-in-class products can outperform corporate scale. But maybe the real advantage was even simpler: surgeons and their teams demand a company genuinely obsessed with biologics, not one treating them as an afterthought alongside hardware. And that's exactly what the market is rewarding. 

nucleus[^]

convene • educate • fund

Building the future of life sciences in Utah

We **convene** innovators, **fund** bold ideas,
and **educate** the next generation to turn
discovery into lasting impact.

POWERING UTAH'S LIFE SCIENCE INNOVATION



\$4M INVESTED IN UTAH LIFE SCIENCE COMPANIES

Investing patient capital
in Utah's most promising
life science and deep
tech startups to
accelerate innovation
and commercial success.



OVER \$25M IN LIFE SCIENCE FUNDING SINCE 2021

Empowering Utah
startups with non-dilutive
funding strategies,
SBIR/STTR expertise, and
commercialization
resources.

NUCLEUS FUND PORTFOLIO HIGHLIGHT



BLOOM SURGICAL

Empowering laparoscopic surgeons
to resolve intraoperative visual
disruptions with in-abdomen rapid-
response tools, including their
Scope Wiper & Irrigation Cleaning
System (SWICS).

NUCLEUS GROW PARTNER HIGHLIGHT



MOUNTAIN BIO

Building AI-powered infrastructure
that enables seamless healthcare
data integration for next-generation
innovation.

Where Utah's life science breakthroughs become tomorrow's companies.

Whether you're commercializing research, launching a startup, or scaling an innovative business, Nucleus is your partner from idea to impact.

Let's build what's next.

nucleusinstitute.org



BIOUTAH'S ELITE MEMBERS

Elite members provide resources to assist BioUtah with achieving our aggressive goals in delivering value to Utah's life science industry and the state's economy.

Thank you!

LEGACY MEMBERS



PLATINUM MEMBERS



GOLD MEMBERS



SILVER MEMBERS



BRONZE MEMBERS





As biopharmaceutical researchers
keep searching for breakthrough cures
they don't have to look far for inspiration.

In this new era of medicine, where breakthroughs
are transforming prevention and treatment options,
PhRMA is committed to fixing America's health
care system the right way.

PhRMA
RESEARCH • PROGRESS • HOPE

www.PhrMA.org/BetterWay



NOVEMBER 11, 2026
HILTON SALT LAKE CITY CENTER

A large, abstract, colorful sphere composed of swirling, translucent layers of blue, purple, orange, and yellow. The sphere is surrounded by a cloud of small, glowing particles in various colors (blue, orange, purple, yellow) that appear to be floating around it. The background is a dark blue gradient with a subtle pattern of small, glowing particles.

TRANSFORMING T O M O R R O W

UTAHLIFESCIENCESUMMIT.COM

SPONSORED BY **MAYER | BROWN**

PRESENTED BY  **BIOUTAH**